Latest News in the pharma Industry

Research & Development

New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

5 Sep 2016

Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study.

Read more 
New Data: Stiolto Respimat inhalation spray significantly improved exercise capacity in people with COPD

New Data: Stiolto Respimat inhalation spray significantly improved exercise capacity in people with COPD

5 Sep 2016

Tiotropium+olodaterol Respimat along with exercise training and behavior modification significantly increased exercise capacity compared to placebo.

Read more 
Merck pulls the plug on odanacatnib

Merck pulls the plug on odanacatnib

5 Sep 2016

Increased risk of stroke fails to support further development.

Read more 
Biogen’s investigational Alzheimer’s disease treatment aducanumab granted FDA Fast Track Designation

Biogen’s investigational Alzheimer’s disease treatment aducanumab granted FDA Fast Track Designation

2 Sep 2016

Company also provides update on new interim analysis from Phase Ib study.

Read more 
AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus in persistence to treatment

AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus in persistence to treatment

31 Aug 2016

New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide Diskus.

Read more 
Early results show aducanumab removes amyloid plaques in patients with Alzheimer's disease

Early results show aducanumab removes amyloid plaques in patients with Alzheimer's disease

31 Aug 2016

Results provide compelling support for the hypothesis that amyloid build-up is a key factor in driving cognitive decline in Alzheimer's disease.

Read more 
New Repatha analyses show efficacy and safety across risk groups

New Repatha analyses show efficacy and safety across risk groups

30 Aug 2016

Consistently reduced low-density lipoprotein cholesterol in patients across cardiovascular risk subgroups or with familial hypercholesterolemia.

Read more 
Cerecor announces initiation of second CERC-501 Phase II clinical trial in smokers

Cerecor announces initiation of second CERC-501 Phase II clinical trial in smokers

30 Aug 2016

Study to evaluate the effect of CERC-501 on stress-related smoking lapse.

Read more 
Elite announces development and license agreement with SunGen Pharma

Elite announces development and license agreement with SunGen Pharma

29 Aug 2016

Companies will collaborate to develop and commercialize four generic products - two CNS stimulants and two beta blockers.

Read more 
RedHill Biopharma receives approval of a European patent supporting RHB-104 for MS

RedHill Biopharma receives approval of a European patent supporting RHB-104 for MS

29 Aug 2016

Patent expected to be valid until 2032, once granted.

Read more 
Novartis announces positive Phase III results showing efficacy of BAF312

Novartis announces positive Phase III results showing efficacy of BAF312

28 Aug 2016

The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo

Read more 
Biothera expands relationship with Merck, enters collaboration for combination cancer immunotherapy trials in multiple indications

Biothera expands relationship with Merck, enters collaboration for combination cancer immunotherapy trials in multiple indications

25 Aug 2016

Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor Keytruda (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer.

Read more